Dr. Sharvil Patel
Managing Director
Zydus Lifesciences Limited
Zydus Corporate Park, S.G. Highway
Nr. Vashnodevi Circle
Ahmedabad 382482
IndiaFEI 3013712903Issued Aug 29, 2024Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3013712903.
Violations4
Issue DateAug 29, 2024
Product TypeDrugs
StatusClosed
Closeout LetterDec 16, 2025
Letter Details
Firm
Zydus Lifesciences Limited
Location
Dr. Sharvil Patel
Managing Director
Zydus Lifesciences Limited
Zydus Corporate Park, S.G. Highway
Nr. Vashnodevi Circle
Ahmedabad 382482
India
FEI Number
3013712903
Country
India
Issue Date
August 29, 2024
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Closed
Closeout Letter
December 16, 2025
Summary
Zydus Lifesciences Limited's drug manufacturing facility in Gujarat, India was found to have significant Current Good Manufacturing Practice (CGMP) violations that resulted in adulterated pharmaceutical products. The company failed to adequately investigate contamination events, including multiple cross-contamination incidents over a three-month period where one drug product contaminated other products manufactured on shared equipment due to inadequate cleaning procedures. The firm's investigation was insufficient because it failed to consider all impacted batches, all manufacturing equipment involved, and the adequacy of testing methods used to release contaminated products. Additionally, initial cleaning validation studies did not properly assess whether cleaning methods could effectively remove residues from the contaminating drug product.
Zydus Lifesciences Limited FDA Warning Letter, August 29, 2024